NCT06210334 2024-02-20
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
Clinical Trials
39 trialsNCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT05910970 2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3 Unknown
NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
NCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05903456 2023-06-15
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05889949 2023-06-07
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT04967495 2023-05-18
TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Unknown
NCT04368078 2023-03-29
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05675462 2023-03-06
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Phase 1 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT03838796 2022-08-02
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Fudan University
Phase NA Unknown
NCT05391867 2022-05-26
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
Phase NA Unknown
NCT05220020 2022-05-19
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT05339581 2022-04-27
iPLENTY-pvtt
RenJi Hospital
Phase NA Unknown
NCT04443049 2021-10-05
To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.
Institute of Liver and Biliary Sciences, India
Phase NA Unknown
NCT04490694 2021-09-24
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT05056337 2021-09-24
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Shanghai Zhongshan Hospital
Phase 3 Unknown
NCT04531228 2021-09-22
Thalen
Sun Yat-sen University
Phase NA Unknown
NCT04814043 2021-09-22
PLATIC
Sun Yat-sen University
Phase 2 Unknown
NCT05007587 2021-08-16
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Zhejiang Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT04127396 2021-07-23
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Phase 4 Unknown
NCT04961138 2021-07-14
Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT04042805 2021-03-02
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04170179 2021-02-23
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University
Phase 2 Unknown
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT04741165 2021-02-05
Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT04560751 2020-09-23
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
Zhejiang Cancer Hospital
Unknown
NCT04443322 2020-09-22
Dulect2020-1
RenJi Hospital
Phase NA Unknown
NCT04319484 2020-03-24
LLTHVV
RenJi Hospital
Phase 2/3 Unknown
NCT04273100 2020-02-17
PLTHCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04241523 2020-01-27
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04227808 2020-01-14
Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown
NCT04168944 2019-11-19
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
RenJi Hospital
Phase 2/3 Unknown
NCT04053972 2019-08-13
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University
Phase 3 Unknown
NCT04053985 2019-08-13
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 3 Unknown
NCT03775395 2019-01-03
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown